SLC2A1 and neoplasm: Indeed, BAY-876 inhibitor [N4-1-(4-cyanobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl-7-fluo­roquinoline-2,4-dicarboxamide] demonstrates notable effectiveness in suppressing GLUT1 expression resulted in decreased glycolysis and a significant reduction of tumor growth in both in vivo and in vitro studies [89].